Renal nutrition formula: lower protein formula for CKD not on dialysis
Medical nutrition (FSMP)Renal formulaLower protein (LP)1 registration Kidney notes reviewed
Company: HEXAGON NUTRISCIENCELast updated:Audience: Licensed health professionals
Registered with the Philippine FDA as a FOOD FOR SPECIAL MEDICAL PURPOSES — for the dietary management of patients under medical supervision. Use with a physician's or dietitian's guidance; it is a food, not a drug.
CKD · dialysis · transplant
Kidney notes
PENTASURE 1.0 is a renal nutrition formula (HEXAGON NUTRISCIENCE) registered with the Philippine FDA as a food for special medical purposes (FSMP), not as a drug or a food supplement. Its job is to help a patient meet energy and protein targets when food alone falls short.
What each variant is for
PENTASURE 1.0 LP: lower-protein version: for CKD not on dialysis; fit the formula's protein within a low-protein prescription (0.55 to 0.6 g/kg/day, or 0.6 to 0.8 g/kg/day with diabetes) and use it mainly to cover energy. Registered "for the dietary management of people with renal insufficiency (pre-dialysis)".
How it fits the KDOQI 2020 nutrition guideline
Chronic kidney disease (CKD) stages 3 to 5, not on dialysis, metabolically stable, without diabetes: KDOQI 2020 recommends a low-protein diet of 0.55 to 0.6 g/kg body weight per day, or a very low-protein diet of 0.28 to 0.43 g/kg/day with ketoacid analogues, under close dietitian supervision. With diabetes the target is 0.6 to 0.8 g/kg/day.
Maintenance hemodialysis or peritoneal dialysis, metabolically stable: 1.0 to 1.2 g/kg body weight per day.
CKD stages 3 to 5 or on dialysis, at risk of or with protein-energy wasting (PEW): KDOQI suggests a minimum 3-month trial of oral nutritional supplements when dietary counseling alone does not reach energy and protein needs.
A renal formula is a tool for reaching these targets. The lower-protein (LP) version has to fit inside the daily protein allowance of a patient not on dialysis; the higher-protein (HP) version helps a dialysis patient reach the higher target. Neither replaces individualized counseling by a renal dietitian.
Evidence
No clinical study of PENTASURE 1.0 itself in kidney disease was found in a PubMed brand-name search (November 17, 2026); the evidence below is for oral nutritional supplements as a class.
Cochrane review (Mah 2020): 22 randomized trials, 1,278 adults on dialysis. Oral protein-based supplements probably raise serum albumin (mean difference 0.19 g/dL, moderate certainty), more so on hemodialysis and in malnourished patients. Deaths were not reported as an outcome in any trial, so the effect on survival and other clinical outcomes is uncertain.
Meta-analysis (Liu 2023): 22 randomized trials, 1,185 patients on dialysis. Supplements raised serum albumin (1.26 g/L), body mass index and handgrip strength, with no significant change in serum phosphorus, potassium or C-reactive protein.
Renal-specific supplement trial (Fouque 2008): 86 hemodialysis patients with low intake randomized to a renal-specific oral supplement (another brand) for 3 months or standard care. Intake rose in the per-protocol analysis (not clearly in intention-to-treat), phosphate and binder use did not increase, and subjective global assessment and quality of life improved.
Observational data: in a large matched cohort of hypoalbuminemic hemodialysis patients, intradialytic supplements were associated with lower mortality (adjusted intention-to-treat hazard ratio 0.91, 95% CI 0.85 to 0.98), with residual confounding possible (Lacson 2012); a smaller disease-management cohort found fewer hospitalizations but no significant mortality difference (Cheu 2013).
Evidence for supplements in CKD not on dialysis is thinner: the trials above are in dialysis patients. In non-dialysis CKD, the formula's role is to cover energy needs while staying within a prescribed low-protein diet.
Cautions in kidney disease
Potassium, phosphorus and sodium: renal formulas are marketed as lower in these than standard formulas, but amounts differ by brand, variant and reformulation. Check the product label and count every serving in the day's potassium and phosphorus; monitor serum levels after starting.
Fluid: a ready-to-drink serving, or the water used to mix a powder, counts toward the interdialytic fluid allowance.
Variant mismatch: an HP (dialysis) version taken by a patient on a low-protein diet before dialysis adds protein beyond the prescription; an LP version on dialysis may not deliver enough protein.
Diabetes: these formulas contain carbohydrate. Check glucose after starting, especially with insulin or sulfonylureas, and use the diabetic protein target (0.6 to 0.8 g/kg/day) before dialysis.
Cost: these are paid out of pocket in most settings. Reserve them for patients with, or at risk of, protein-energy wasting, set a goal (intake, weight, albumin, subjective global assessment), and reassess after about 3 months.
A food for special medical purposes is meant for use under medical supervision; it supplements meals and does not replace them.
Bottom line
A reasonable choice for a patient with, or at risk of, protein-energy wasting whose intake falls short after dietitian counseling: match the variant to the stage (LP before dialysis, HP on dialysis), check the label for potassium, phosphorus and fluid, and reassess after about 3 months. Supplements raise albumin and intake; effects on survival are not proven by trials.
Sources
Ikizler, T. A., Burrowes, J. D., Byham-Gray, L. D., Campbell, K. L., Carrero, J.-J., Chan, W., Fouque, D., Friedman, A. N., Ghaddar, S., Goldstein-Fuchs, D. J., Kaysen, G. A., Kopple, J. D., Teta, D., Yee-Moon Wang, A., & Cuppari, L. (2020). KDOQI clinical practice guideline for nutrition in CKD: 2020 update. American Journal of Kidney Diseases, 76(3 Suppl 1), S1–S107. https://doi.org/10.1053/j.ajkd.2020.05.006
Mah, J. Y., Choy, S. W., Roberts, M. A., Desai, A. M., Corken, M., Gwini, S. M., & McMahon, L. P. (2020). Oral protein-based supplements versus placebo or no treatment for people with chronic kidney disease requiring dialysis. Cochrane Database of Systematic Reviews, 5(5), CD012616. https://doi.org/10.1002/14651858.CD012616.pub2
Liu, P. J., Guo, J., Zhang, Y., Wang, F., & Yu, K. (2023). Effects of oral nutritional supplements on the nutritional status and inflammatory markers in patients on maintenance dialysis: A systematic review and meta-analysis of randomized clinical trials. Clinical Kidney Journal, 16(11), 2271–2288. https://doi.org/10.1093/ckj/sfad130
Fouque, D., McKenzie, J., de Mutsert, R., Azar, R., Teta, D., Plauth, M., & Cano, N. (2008). Use of a renal-specific oral supplement by haemodialysis patients with low protein intake does not increase the need for phosphate binders and may prevent a decline in nutritional status and quality of life. Nephrology Dialysis Transplantation, 23(9), 2902–2910. https://doi.org/10.1093/ndt/gfn131
Lacson, E., Jr., Wang, W., Zebrowski, B., Wingard, R., & Hakim, R. M. (2012). Outcomes associated with intradialytic oral nutritional supplements in patients undergoing maintenance hemodialysis: A quality improvement report. American Journal of Kidney Diseases, 60(4), 591–600. https://doi.org/10.1053/j.ajkd.2012.04.019
Cheu, C., Pearson, J., Dahlerus, C., Lantz, B., Chowdhury, T., Sauer, P. F., Farrell, R. E., Port, F. K., & Ramirez, S. P. B. (2013). Association between oral nutritional supplementation and clinical outcomes among patients with ESRD. Clinical Journal of the American Society of Nephrology, 8(1), 100–107. https://doi.org/10.2215/CJN.13091211
Reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. renalcarematters.com, reviewed
Variants and registered use
LP and HP are the manufacturer's labels for the lower-protein and higher-protein versions, as registered. Per-serving protein, energy, potassium, phosphorus, sodium and fluid differ between versions and change with
reformulation: check the product label.
Variant
Registered use
Flavor
FR numbers
LP · lower protein, for CKD not on dialysis
For the dietary management of people with renal insufficiency (pre-dialysis)
1 current FSMP registration under the brand PENTASURE 1.0. Registration status changes;
confirm a product's current status on the FDA verification portal using its FR number.
FORMULATED POWDERED DRINK-FOOD FOR SPECIAL MEDICAL PURPOSES FOR THE DIETARY MANAGEMENT OF PEOPLE WITH RENAL INSUFFICIENCY (PRE-DIALYSIS) VANILLA FLAVOR
Composition
The FDA record names the product type and its registered use, not the full composition. Check the product label for protein, energy, potassium, phosphorus, sodium and fluid per serving.
For the dietary management of people with renal insufficiency (pre-dialysis)
Flavor
Vanilla
Form
Powder
Company
HEXAGON NUTRISCIENCE
Issued
October 21, 2025
Valid until
October 21, 2030
FDA risk class
High Risk
Application
Renewal
For health professionals. Data come from the FDA Philippines food-product
registration database and may lag behind the official record. A food-for-special-medical-purposes registration means the product may be sold as a food for the dietary management of patients under medical supervision; it is not a drug approval. Not a substitute for clinical judgment.